Our team at CRC constantly develops faster, cheaper and safer techniques to prepare PET tracers. They are able to produce multiple high-quality ¹⁸F based tracers suitable for clinical studies (GMP facilities).

For more information about our services and capabilities in radiopharmaceutical development and production, click here.

More specifically, within Alzheimer’s disease, following tracers are being developed: